Practical considerations for active machine learning in drug discovery
Author(s)
Reker, Daniel
DownloadReker_DDT_accepted.pdf (293.0Kb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
Active machine learning enables the automated selection of the most valuable next experiments to improve predictive modelling and hasten active retrieval in drug discovery. Although a long established theoretical concept and introduced to drug discovery approximately 15 years ago, the deployment of active learning technology in the discovery pipelines across academia and industry remains slow. With the recent re-discovered enthusiasm for artificial intelligence as well as improved flexibility of laboratory automation, active learning is expected to surge and become a key technology for molecular optimizations. This review recapitulates key findings from previous active learning studies to highlight the challenges and opportunities of applying adaptive machine learning to drug discovery. Specifically, considerations regarding implementation, infrastructural integration, and expected benefits are discussed. By focusing on these practical aspects of active learning, this review aims at providing insights for scientists planning to implement active learning workflows in their discovery pipelines.
Date issued
2020-07Department
Koch Institute for Integrative Cancer Research at MITJournal
Drug Discovery Today: Technologies
Publisher
Elsevier BV
Citation
Reker, Daniel. "Practical considerations for active machine learning in drug discovery." Forthcoming in Drug Discovery Today: Technologies (July 2020): http://dx.doi.org/10.1016/j.ddtec.2020.06.001 © 2020 Elsevier Ltd
Version: Author's final manuscript
ISSN
1740-6749